JPMorgan raised the firm’s price target on Roivant Sciences (ROIV) to $33 from $31 and keeps an Overweight rating on the shares. The firm updated the company’s model to reflect the settlement with Moderna. JPMorgan sees the settlement as a “major overhang lift” for Roivant, saying investor attention now turns solely to the company’s clinical readouts.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ROIV:
- Midday Fly By: Stocks climb as oil prices pull back
- Video: Moderna advances as settlement seen removing share overhang
- Morning Movers: Moderna rises after entering COVID settlement agreement
- Unlocking Value from IP Settlement and Pipeline Catalysts: Why Roivant Deserves a Buy Rating
- Moderna resolves litigation with Arbutus, to pay up to $2.25B in settlement